# Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct05451290/  
OnCo record `nct05451290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab, gemcitabine, oxaliplatin and S-1 in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital of Zhejiang University, active and no longer recruiting.

## Summary

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT05451290 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 30 participants, started 2022-11-01 and due to reach its primary completion in 2024-12-31. Interventions recorded: Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur. Conditions listed: Advanced Biliary Tract Carcinoma. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT05451290
- Phase: 2
- Setting: Camrelizumab Plus Apatinib Combined With GEMOX (Gemcitabine and Oxaliplatin ) in the Perioperative Treatment of Locally Advanced Biliary Tract Malignancies: A Prospective, Multicenter, Phase Ⅱ Study
- Sponsor: First Affiliated Hospital of Zhejiang University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05451290: https://clinicaltrials.gov/study/NCT05451290

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct05451290.json